[1]修立恒,李佳林,李常栋,等.玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察[J].眼科新进展,2015,35(11):1067-1070.[doi:10.13389/j.cnki.rao.2015.0292]
　XIU Li-Heng,LI Jia-Lin,LI Chang-Dong,et al.Pathological myopia combined with choroidal neovascularization treated by intravitreal injection of ranibizumab[J].Recent Advances in Ophthalmology,2015,35(11):1067-1070.[doi:10.13389/j.cnki.rao.2015.0292]
点击复制

玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
35卷
期数:
2015年11期
页码:
1067-1070
栏目:
应用研究
出版日期:
2015-11-05

文章信息/Info

Title:
Pathological myopia combined with choroidal neovascularization treated by intravitreal injection of ranibizumab
作者:
修立恒; 李佳林; 李常栋; 沈志斌
635000　四川省达州市，达州市中心医院眼科
Author(s):
XIU Li-Heng ;  LI Jia-Lin ;  LI Chang-Dong ; SHEN Zhi-Bin
Department of Ophthalmology , Dazhou Central Hospital , Dazhou 635000 . Sichuan Province , China
关键词:
雷珠单抗; 病理性近视; 脉络膜新生血管
Keywords:
ranibizumab ;  pathologic myopia ;  choroidal neovascularization
DOI:
10.13389/j.cnki.rao.2015.0292
文献标志码:
A
摘要:
目的　观察玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管（ｃｈｏｒｏｉｄａｌｎｅｏｖａｓｃｕｌａｒｉｚａｔｉｏｎ，ＣＮＶ）的临床疗效及安全性。方法　回顾性分析１８例１８眼病理性近视患者的临床资料。玻璃体内注射雷珠单抗０．５ｍｇ（０．０５ｍＬ），术后每个月随访时行最佳矫正视力（ｂｅｓｔｃｏｒｒｅｃｔｅｄｖｉｓｕａｌａｃｕｉｔｙ，ＢＣＶＡ）、眼底彩照、光学相干断层扫描（ｏｐｔｉｃａｌｃｏｈｅｒｅｎｃｅｔｏｍｏｇｒａｐｈｙ，ＯＣＴ）检查，术后１个月、３个月、６个月随访时行眼底荧光血管造影（ｆｌｕｏｒｅｓｃｅｎｃｅｆｕｎｄｕｓａｎｇｉｏｇｒａｐｈｙ，ＦＦＡ）检查。随访过程中发现ＣＮＶ部分闭合或持续渗漏者则再次予以玻璃体内注射雷珠单抗。比较治疗前后ＢＣＶＡ、ＯＣＴ、眼底彩照及ＦＦＡ检查结果，观察其临床疗效及安全性。结果　术后１个月、３个月、６个月随访时，ＢＣＶＡ均较术前明显提高（Ｆ＝１１．３５４，Ｐ＜０．０５）；黄斑中心凹厚度均较术前明显降低（Ｆ＝４．２４２，Ｐ＜０．０５）。术后６个月随访时，１６眼视力提高２行以上，２眼视力稳定；眼底彩照示所有患眼黄斑区出血吸收，ＦＦＡ检查示１４眼ＣＮＶ完全闭合，４眼大部分闭合。玻璃体内注射雷珠单抗平均次数为２．５６次，其中３眼行１次，８眼行２次，５眼行３次，２眼行４次。随访期间所有患者均未出现眼部及全身并发症。结论　玻璃体内注射雷珠单抗治疗病理性近视合并ＣＮＶ是安全有效的。
Abstract:
Objective To evaluate the effects and safety of pathologic myopia with choroidal neovascularization( CNV ) treated by intravitreal injection of ranibizumab. Methods The medical records of 18 patients with pathological myopia and CNV were retrospectively reviewed. The patients was followed up monthly after intravitreal injection of rarubizumab 0. 5 mg ( 0. 05 mL) .best corrected visual acuity , fundus examination and OCT were observed. FFA was performed at I month.3 months.6 months after operation. During follow-up , if part of a closed or continuous leakage of CNV was found .intravitreal injection of Rarubizumab was done again. The results of BCVA,OCT, FFA and fundus examination before and after treatment were compared , and the clinical efficacy and safety were observed. Results At I month .3 months.6 months after operation .best corrected visual acuity in all eyes was improved compared with pre-operation , and the difference was significant ( F = 11. 354 .P < 0. 05 ) ; Central macular thickness in all eyes were reduced, and the difference was significant ( F = 4. 242 .P < 0. 05 ) . At 6 months after operation ,visual acuity of 16 eyes( 88. 8g% ) increased more than 2 lines. visual acuity of 2 eyes( 11. 11% ) remained stable. Fundus photograph showed hemorthage absorption of macular region rn all eyes. FFA showed CNV for 14 eyes ( 77. 78% ) completely closed, and 4 eyes ( 22. 22% ) mostly closed. The average number of intravitreal injection of Ranibizumab was 2. 56 .in which 3 eyes for I time ,10 eyes for 2 times,5 eyes for 3 times.and 2 eyes for 4 times. During follow-up , ocular and systemic complication was not found in all patients. Conclusion Treatment of pathologic myopia with CNV by intravitreal injection of ranibizumab is safe and effective.

相似文献/References:

[1]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[2]黄志坚 宋艳萍 金中秋 丁琴 陈中山.光动力疗法联合玻璃体内注射Bevacizumab治疗病理性近视合并脉络膜新生血管[J].眼科新进展,2013,33(4):000.
[3]王晓霞 史志洁 林娜 刘晓瑞.光学相干断层扫描在病理性近视黄斑裂孔中的应用[J].眼科新进展,2013,33(9):000.
[4]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[5]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[6]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].眼科新进展,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
[7]陆秉文,吴星伟. Ranibizumab玻璃体内注射治疗病理性近视脉络膜新生血管研究进展[J].眼科新进展,2014,34(9):897.[doi:10.13389/j.cnki.rao.2014.0248]
[8]章晖,叶波,邱新文,等.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975.[doi:10.13389/j.cnki.rao.2014.0270]
[9]丁雯芝,邹俊.病理性近视脉络膜新生血管发病机制的研究进展[J].眼科新进展,2014,34(10):987.[doi:10.13389/j.cnki.rao.2014.0274]
[10]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(11):246.[doi:10.13389/j.cnki.rao.2015.0066]
[11]刘李平,宋徽,冀垒兵,等.玻璃体内注射雷珠单抗治疗病理性近视黄斑部脉络膜新生血管[J].眼科新进展,2016,36(7):667.[doi:10.13389/j.cnki.rao.2016.0177]
　LIU Li-Ping,SONG Hui,JI Lei-Bing,et al.Intravitreal ranibizumab injections for pathologic myopia macular choroidal neovascularization[J].Recent Advances in Ophthalmology,2016,36(11):667.[doi:10.13389/j.cnki.rao.2016.0177]
[12]孙早荷,万光明,钱诚,等.玻璃体内注射雷珠单抗治疗病理性近视继发脉络膜新生血管[J].眼科新进展,2018,38(10):925.[doi:10.13389/j.cnki.rao.2018.0219]
　SUN Zao-He,WAN Guang-Ming,QIAN Cheng,et al.Efficacy of intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to pathological myopia[J].Recent Advances in Ophthalmology,2018,38(11):925.[doi:10.13389/j.cnki.rao.2018.0219]

更新日期/Last Update: 2015-11-03